By Atanu Saha, Narinder Walia and Yong Xu ( July 20, 2026, 5:51 PM EDT) -- In March, indirect purchasers of Novo Nordisk's GLP-1 drug Victoza filed a lawsuit alleging Novo Nordisk conspired to delay generic entry by approximately 16 months, from February 2023 to June 2024.[1] The case, Uniformed Fire Officers Association Retired Officers Family Protection Plan v. Novo Nordisk Inc., is currently being litigated in the U.S. District Court for the Eastern District of New York....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.